Does anyone know how the current syudies by BDM into this disease are going and how the peptide medication compares to other processes. I understand it stimulates growth of new retinal pigmented epithelial cells and inhibits the growth of choroidal endothelial cells associated with unwanted neovascularisation. Has there been any news from the studies in Russia
Eli Lilly and co have a study for which the results have not been announced yet that I can see. See http://www.clinicaltrials.gov/ct/gui/show/NCT00090519?order=4
How does the peptide treatment compare to Ruboxistaurin.
There area range of other studies around from the University Eye Clinic in Mannheim, as well as Intravitreal injection of triamcinolone acetonide etc.
Any information would be appreciated on how these compare to BDM's peptide process
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
2.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $31.26M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 448 | 2.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.4¢ | 388415 | 4 |
View Market Depth
| Last trade - 10.02am 15/09/2025 (20 minute delay) ? |
| BDM (ASX) Chart |
Day chart unavailable